Novel bifluorescent Zn(II)–cryptolepine–cyclen complexes trigger apoptosis induced by nuclear and mitochondrial DNA damage in cisplatin-resistant lung tumor cells

Hydrazylpyridine salicylaldehyde–copper(ii)–1,10-phenanthroline complexes as potential anticancer agents: synthesis, characterization and anticancer evaluation

“…It regulated the production of the associated-proteins. 31,43,44 First, the effect of Cugdupt8 (0.5 μM) and Cugdupt1 (10.0 μM) on the MRCC-I/IV and ATP production in A549cis cells was determined using a kit by following the manufacturer's instructions. Tables 3–5 show that MRCC-I, MRCC-IV and ATP levels of Cugdupt8 (0.5 μM) decreased by 30.4%, 33.8% and 31.1% as compared to those of the control cells; however, the inhibition of Cugdupt1 (10.0 μM) on the MRCC-I, MRCC-IV and ATP production was lower than that of Cugdupt8 (0.5 μM).…”

“…These findings explain that Cugdupt8 (0.5 μM) and Cugdupt1 (10.0 μM) could remarkably influence the levels of MRCC-I, MRCC-IV and ATP and may further induce the cell death mode in A549cis cells. 31,42,43 Next, nine mitophagy associated proteins were measured by western blotting and immunofluorescence to study the rate of A549cis cell apoptosis with Cugdupt8 (0.5 μM) and Cugdupt1 (10.0 μM). 31,43–47 Fig.…”

“…In addition, the methods for investigating the in vitro anticancer mechanism of Cugdupt1–Cugdupt9 were similar to those in our previously reported protocol. 31…”

New anti-cancer explorations based on metal ions

“…X-ray absorption fine structure (XAFS) analysis proved that dopants were inside the quantum dots rather than on the surface, which can effectively overcome the "self-purification" effect. Wang's team [ 257 ] designed Zn 2+ –cryptolepine–cyclen complexes with dual fluorescence characteristics. The selective fluorescence imaging of the nucleus and mitochondria of A549R cancer cells was conducted with a promising in vivo safety profile.…”

The strongin vitroandvivocytotoxicity of three new cobalt(ii) complexes with 8-methoxyquinoline

“…The Pt-based drug cisplatin and its related complexes comprise the first line of treatment for various types of neoplasms in the fight against cancer. 1–3 However, the clinical application of cisplatin and its analogues has been limited due to their side effects, such as neurotoxicity, drug resistance, emetogenicity, and nephrotoxicity. 4 To overcome these drawbacks, a large number of non-platinum anticancer drugs with less toxicity, greater effectiveness, and higher target specificity have been discovered.…”